Loading...
•
Sep 30, 2020
Lexicon Pharmaceuticals Q3 2020 Earnings Report
Lexicon Pharmaceuticals reported its third quarter 2020 financial results and provided a clinical update.
Key Takeaways
Lexicon Pharmaceuticals reported a decrease in revenues to $6.6 million, primarily due to the termination of the alliance with Sanofi in the previous year. Net income was $82.6 million, driven by a gain on the sale of XERMELO. The company is focusing on the advancement of LX9211 and has commenced a Phase 2 study in diabetic peripheral neuropathic pain.
Commenced patient dosing in a Phase 2 study of LX9211 for diabetic peripheral neuropathic pain.
Preparing to commence an additional Phase 2 study of LX9211 in post-herpetic neuralgia.
Reduced outstanding debt by more than 90%, including the elimination of its $150 million secured term loan.
XERMELO U.S. net sales were $6.5 million prior to the completion of its sale to TerSera Therapeutics LLC.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Net Product Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.com Forward Guidance
Lexicon Pharmaceuticals anticipates several milestones in the near future.
Positive Outlook
- Initiation of a Phase 2 study for LX9211 in post-herpetic neuralgia in Q4 2020.
- Presentation of data from sotagliflozin SOLOIST and SCORED Phase 3 studies at the American Heart Association Scientific Sessions 2020 in Q4 2020.
- Phase 2 study results in diabetic peripheral neuropathic pain expected in Q4 2021.
- Phase 2 study results in post-herpetic neuralgia expected in Q4 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income